Blog
RSS FeedPosted by Michael Wonder on 07 Jun 2023
Axicabtagene ciloleucel for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy
7 June 2023 - NICE has published final evidence-based recommendations on the use of axicabtagene ciloleucel (Yescarta) for the treatment ...
Posted by Michael Wonder on 08 Aug 2018
Comparing the ICERs in medicine reimbursement submissions to NICE and PBAC—does the presence of an explicit threshold affect the ICER proposed?
8 August 2018 - The English NICE and the Australian PBAC require evidence that a new medicine represents value for money ...
Posted by Michael Wonder on 02 Aug 2016
Rare cancer drug which significantly delays progression of advanced thyroid cancer is left off relaunched Cancer Drugs Fund
2 August 2016 - People with radioiodine refractory differentiated thyroid cancer are overlooked as Lenvima (lenvatinib mesylate) is not scheduled for ...